HPS Pharmacies wish to advise that Hospira, in consultation with the Therapeutic Goods Administration (TGA), have given notice of a drug recall of:
DBL® Methotrexate Tablets 2.5mg (bottles of 30 tablets)
This recall has been issued due to these bottles of DBL® Methotrexate tablets 2.5mg x 30 being supplied in containers without child-resistant closures, which presents a risk to children of accidental ingestion of these poisons. There is no concern with the quality or safety of the tablets themselves.
As this recall represents all supplies of DBL® Methotrexate tablets 2.5mg x 30 currently available, HPS Pharmacies are pleased to offer repackaging of existing supplies to enable continuation of therapy. As other brands of methotrexate tablets are registered in Australia and available under the Pharmaceutical Benefits Scheme, no supply shortages are anticipated.
Please inspect your stocks and quarantine all products from the batches listed above for return to your supplier for a refund.
Retain this notice in a prominent position, including in other related business units for one month, or until normal supply resumes. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact your pharmacist at HPS Pharmacies, or Hospira on 1300 046 774.
Information regarding expected dates for supply may vary subject to delays which are out of our control. HPS Pharmacies does not accept responsibility for such changes but will endeavour to keep our clients updated as information is made available from drug manufacturers or wholesalers.